Eric Rhodes

CEO at ERS Genomics, Ireland

Content by Eric Rhodes:

 Research Field Cell & gene therapy

Welcome to the CRISPR Powerhouse

| Eric Rhodes | 4 min read

Why 2023 is the year that antibody manufacturers should embrace CRISPR gene editing.
Register to The Translational Scientist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts

Register

October Issue of The Translational Scientist